Upfront triple combination therapy in pulmonary arterial hypertension: a pilot study.
Sitbon, Olivier; Jaïs, Xavier; Savale, Laurent; Cottin, Vincent; Bergot, Emmanuel; Macari, Elise Artaud; Bouvaist, Hélène; Dauphin, Claire; Picard, François; Bulifon, Sophie; Montani, David; Humbert, Marc; Simonneau, Gérald.
Eur Respir J
; 43(6): 1691-7, 2014 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-24627535
Long survival of congenital alveolar capillary dysplasia patient with NO inhalation and epoprostenol: effect of sildenafil, beraprost and bosentan.
Impact of first-line sildenafil monotreatment for pulmonary arterial hypertension.
Long-term experience after transition from parenteral prostanoids to oral agents in patients with pulmonary hypertension.
Combination therapy with bosentan and sildenafil in Eisenmenger syndrome: a randomized, placebo-controlled, double-blinded trial.
Behandling av idiopatisk pulmonal arteriell hypertensjon.
Addition of sildenafil in patients with pulmonary arterial hypertension with inadequate response to bosentan monotherapy.
Survival after the initiation of combination therapy in patients with pulmonary arterial hypertension: an Australian collaborative report.
Addition of prostanoids in pulmonary hypertension deteriorating on oral therapy.
Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial.
Sildenafil and beraprost combination therapy in patients with pulmonary hypertension undergoing valvular heart surgery.